Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year
Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was ...
Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, ...
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test
-- Ortho's new VITROS® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection. -- Ortho is the first company to have an EUA for both a quantitative IgG a...
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care...
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu
RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now ...
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 - Ortho is ...
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific
Introducing VITROS® QC Solutions, taking your lab to the next level with Thermo Scientific™ MAS™ Quality Controls RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, today announced its...
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care ...
Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response
- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody t...
Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark
- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization of SARS-CoV-2 serological methods - The test gives clinicians and public health leaders a standa...
Global Transfusion Medicine Leader Ortho Clinical Diagnostics Launches Next Gen ORTHO VISION® Swift Platform
ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ORTHO VISION® Swift and ORTHO VISION® Max Swi...
Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing
Silver Award Recognizes Antibody and Antigen Tests RARITAN, N.J., April 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious silver 2021 Edison Award for its VITROS® C...
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media
RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020. The CE Mark allows for ...
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense
RARITAN, N.J., April 1, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Def...
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data
RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antige...
Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results
- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune response (acquired naturally or through vaccination) to SARS-CoV-2 - These new anti-SARS-CoV-2 ant...
Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering
RARITAN, N.J., Feb. 5, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the cl...
Ortho Clinical Diagnostics Announces Pricing of Initial Public Offering
RARITAN, N.J., Jan. 28, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its i...
